About this BPC-157 TB-500 reading room.

What this site is

MD Wolverine is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 TB-500 "Wolverine" blend. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The approach is a botanist's field-book. The Wolverine blend is two distinct peptides, so we mount them as two specimens — a 15-residue body-protection compound beside a 7-residue actin-binding fragment — each with its label, its citation, and its caveat written in the margin. Where the literature is firm, we say so plainly. Where it stops, we mark the gap and leave it visible.

On the "MD" in the name

The "MD" in this domain is editorial framing, not a claim about services. It signals the measured, annotated register of a clinical field-notebook — careful, provenance-first, and slow to overclaim. It does not mean a doctor staffs this site, that consultations are offered, or that prescriptions are written here. No medical professional is implied, named, or invented anywhere on these pages.

This distinction matters because the subject invites overreach. The Wolverine pairing is discussed in athlete forums as a cure-all for any injury. The published record is narrower and more honest: preclinical, single-compound, largely from animal models, with no controlled study of the combination ^[8]. Our job is to keep the page to that record.

How we handle sources

Every quantitative claim on this site is tied to a numbered citation in the references register, resolving to a PubMed entry, a DOI, or an FDA page. We draw on the foundational peptide literature — the transected-tendon BPC-157 result ^[1], the VEGFR2 angiogenesis work ^[2], the G-actin crystal structure ^[3] — and on recent reviews that bound the evidence, including a 2025 systematic review ^[8] and a 2026 Sports Medicine review ^[9].

We are deliberate about what we do not do. We do not aggregate forum protocols, we do not report a community "loading" schedule as if it were a finding, and we do not soften the two structural caveats — the fragment-versus-full-protein provenance gap and the absence of any controlled combination study ^[4][8]. Where the marketing on this blend outruns the published evidence, the gap is the story, and we leave it on the page.

Regulatory facts are kept separate and conservative. We state present-tense status cited to FDA, and we never present a possible future decision as settled. The result is a digest you can audit line by line — a record, not a recommendation.